Journal of Global Antimicrobial Resistance (Dec 2024)

In Vitro Activities of Ceftazidime-Avibactam and Comparator Agents Against Enterobacterales and Pseudomonas aeruginosa Collected in Turkey and the Middle East: ATLAS Global Surveillance Program 2018-2022

  • Meredith Hackel,
  • Gregory Stone,
  • Katherine Perez,
  • Daniel Sahm

Journal volume & issue
Vol. 39
p. 12

Abstract

Read online

BACKGROUND: Avibactam (AVI) is a non-β-lactam β-lactamase inhibitor that when combined with the β-lactam ceftazidime (CAZ) has demonstrated activity against Class A, Class C and some Class D enzymes. This study evaluated the in vitro activity of CAZ-AVI against Enterobacterales and Pseudomonas aeruginosa isolates collected in Turkey and the Middle East as part of the global Antimicrobial Testing Leadership and Surveillance (ATLAS) program in 2018-2022. METHODS: In 2018-2020, 6,335 Enterobacterales and 2,468 P. aeruginosa isolates were collected from 17 medical centers in (n/% of total); Turkey (2,807/31.9%), Israel (2,532/28.8%), Kuwait (2,030/23.1%), Qatar (522 (5.9%), Saudi Arabia (484/5.5%), and Jordan (428/4.9%). Antimicrobial susceptibility testing was performed by broth microdilution following CLSI guidelines and interpreted using EUCAST 2024 breakpoints. RESULTS: CAZ-AVI was active against more Enterobacterales isolates than all comparators (96.4% susceptible; MIC90 = 1 mg/L). Meropenem and amikacin were also active against this population, with 91.7% and 91.9% of the isolates inhibited, respectively. CAZ-AVI activity was >93% for all countries, except for Jordan (87.9% susceptible). CAZ-AVI was the most active agent tested against P. aeruginosa (90.8% susceptible; MIC90 = 8 mg/L). Amikacin was also active against this population, with 90.5% of the isolates inhibited. CAZ-AVI activity was >90% for all countries, except for Kuwait (87.9% susceptible) and Qatar (78.3% susceptible). CONCLUSIONS: CAZ-AVI exhibited potent in vitro activity against Enterobacterales and P. aeruginosa from Turkey and the Middle East. These data suggest CAZ-AVI remains an effective therapeutic option for the treatment of Enterobacterales and P. aeruginosa infections in this region.

Keywords